Core Insights - STRATA Skin Sciences, Inc. participated in the 2025 Ibero-Latin American Congress of Dermatology (TeraCILAD) showcasing its XTRAC® excimer laser and TheraclearX® acne therapy system [1][4] - By the end of 2025, STRATA expects to have over 12 new recurring TheraclearX® accounts in Mexico, indicating a growing adoption of this acne treatment by dermatologists [1][5] Conference Presentations & Clinical Insights - Dr. Melissa Lomeli presented her experience with TheraclearX® at TeraCILAD, highlighting the potential for acne improvement in just one 20-minute session [3] - Dr. Henry Lim discussed the efficacy of XTRAC 308 nm Excimer Laser Therapy for treating vitiligo, psoriasis, and atopic dermatitis [3] Market Context - STRATA engaged with leading dermatologists at TeraCILAD to present the clinical performance of its technologies, with XTRAC® recognized for treating inflammatory and autoimmune skin disorders and TheraclearX® gaining traction as a non-pharmaceutical acne solution [4][7] - The interest from dermatologists in effective, non-systemic treatment options was evident, reinforcing the value of STRATA's technologies in improving patient outcomes [5] Strategic Outlook - STRATA aims to expand access to advanced dermatology solutions across Latin America and globally, with a focus on engaging key opinion leaders and growing recurring revenue opportunities through device-based therapies [6][8] - The company anticipates that fully developed partner clinics could generate upwards of $30,000 in annual revenue per clinic from TheraclearX® placements [6]